Key Points
- Christopher Sarchi sold 5,208 shares of Replimune on Nov. 17 at an average price of $9.10 for about $47,393, reducing his stake by 4.06% to 123,088 shares.
- Replimune stock traded up to $9.14 (≈+1.6%) with a market cap of $716.6M; the company reported quarterly EPS of -$0.90, missing estimates and sitting within a 12‑month range of $2.68–$17.00.
- Analyst views are mixed but the consensus is a "Moderate Buy" with a $9.75 target, even as several firms sharply lowered price targets; institutional ownership is about 92.5%.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 5,208 shares of the firm's stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares of the company's stock, valued at $1,120,100.80. This trade represents a 4.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Replimune Group Stock Up 1.6%
NASDAQ REPL traded up $0.15 during mid-day trading on Thursday, hitting $9.14. The company's stock had a trading volume of 254,651 shares, compared to its average volume of 4,370,007. The firm has a market capitalization of $716.55 million, a price-to-earnings ratio of -2.65 and a beta of 0.80. The company's 50 day simple moving average is $6.62 and its 200 day simple moving average is $7.40. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. Replimune Group, Inc. has a twelve month low of $2.68 and a twelve month high of $17.00.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.03). Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. BMO Capital Markets cut Replimune Group from an "outperform" rating to an "underperform" rating and cut their target price for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Barclays downgraded shares of Replimune Group from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $17.00 to $3.00 in a report on Wednesday, July 23rd. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and increased their target price for the company from $3.00 to $13.00 in a report on Monday, October 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Replimune Group in a research report on Monday. Finally, Piper Sandler raised shares of Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 price objective for the company in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.75.
Check Out Our Latest Stock Report on Replimune Group
Hedge Funds Weigh In On Replimune Group
Institutional investors and hedge funds have recently bought and sold shares of the company. US Bancorp DE lifted its position in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after buying an additional 3,921 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Replimune Group in the 2nd quarter valued at about $69,000. Russell Investments Group Ltd. lifted its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after purchasing an additional 7,569 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Replimune Group by 2,020.8% during the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock valued at $90,000 after purchasing an additional 9,235 shares during the last quarter. 92.53% of the stock is owned by institutional investors.
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
